Early-stage beta
· Errors & gaps may exist · Expanding: US · Nordics · EU
← All companies
/
Top lists
/
Biomarin Pharmaceutical
Biomarin Pharmaceutical
2016–2025 · Healthcare
2026-08-11
Overview
Earnings
Margins
Cash flow
Balance
Capital
Plot
USD millions
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
1 117
1 314
1 491
1 704
1 860
1 846
2 096
2 419
2 854
3 221
Operating profit (EBIT)
−803
−15
−124
−100
−43
−82
161
186
484
409
Net income attributable to shareholders
−630
−117
−78
−24
859
−64
142
168
427
349
EBIT margin
−71,9%
−1,1%
−8,3%
−5,9%
−2,3%
−4,5%
7,7%
7,7%
17,0%
12,7%
Gross margin
81,2%
—
—
78,9%
71,8%
74,5%
76,9%
78,7%
79,7%
77,7%
Operating cash flow
−228
−9
20
48
85
305
176
159
573
828
Free cash flow
−376
—
−133
−115
−52
185
44
52
475
717
Cash
408
598
598
437
649
587
725
755
943
1 312
−1 000
0
1 000
2 000
3 000
4 000
−100,0%
−50,0%
0,0%
50,0%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
1 117
1 314
1 491
1 704
1 860
1 846
2 096
2 419
2 854
3 221
−803
−15
−124
−100
−43
−82
161
186
484
409